Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Government Funding for Eye Health
In many developed and some developing countries, both government and private organizations are actively participating in research and prevention programs focused on eye disorders. These efforts play a crucial role in advancing eye care. The United Kingdom, for example, has made significant strides in this regard. In 2016 alone, the Eye Health Examinations Wales (EHEW) scheme conducted approximately 121,736 eye examinations, demonstrating the commitment to promoting eye health. Furthermore, the National Health Service (NHS) paid for 769,380 general ophthalmic service sight tests in the same year. This substantial support through adequate funding has the potential to significantly boost the growth of the eye care market.
Advancements in Eye Care Products
The continuous progress in treating eye allergies across all age groups is a driving force behind the expansion of the eye care market. Companies like Bausch & Lomb, a subsidiary of Valeant, are at the forefront of these advancements. They are currently developing a new topical corticosteroid called mapracorat, which is undergoing clinical phase II. This ophthalmic solution aims to address issues such as ocular pain, inflammation, eye allergies, and dry eyes. Another player in the field is Merck and Co., offering montelukast, a leukotriene receptor antagonist known for its effectiveness in relieving allergic eye diseases.
Moreover, various manufacturers are actively working on creating innovative ophthalmic solutions, seeking approvals from government regulatory bodies. The heightened competition among existing and emerging market players is fostering an environment conducive to the development of practical and efficient treatments for eye allergies. This competition-driven innovation is a significant factor contributing to the overall growth of the eye care market.
The Importance of Government Support
Favorable government funding is pivotal for the success of research and prevention programs in the field of eye health. This support not only facilitates the exploration of new treatments and diagnostic tools but also ensures that these innovations reach a wider population. In the context of the United Kingdom, the substantial number of eye examinations conducted under the EHEW scheme and the general ophthalmic service sight tests funded by the NHS exemplify the positive impact of government backing.
The Role of Private Organizations
In addition to government support, private organizations play a vital role in advancing eye care. Companies like Bausch & Lomb and Merck and Co. are investing in research and development to bring forth new and improved solutions for various eye conditions. The introduction of mapracorat and montelukast demonstrates the commitment of these organizations to addressing not only common eye problems but also more specific issues like ocular pain and inflammation.
Competition Driving Innovation
The competitive landscape within the eye care market is fostering innovation at an accelerated pace. Manufacturers are not only focused on introducing new products but are also striving to make them more efficient and accessible. This competition-driven innovation benefits consumers by providing a diverse range of treatment options for eye allergies and other conditions.
In conclusion, the combination of favorable government funding, private sector involvement, and competition-driven innovation is propelling the growth of the eye care market. The ongoing advancements in products and treatments not only cater to existing needs but also pave the way for addressing emerging challenges in eye health. The collaborative efforts of governments and private organizations ensure that the future of eye care remains promising and accessible to a wider population.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|
Eye Allergy Treatment Market Highlights:
Eye Allergy Treatment Market Overview:
The eye allergy treatment market is anticipated to reach USD 2,926.92 Million by 2030 at 4.90% CAGR during the forecast period 2022-2030. Some of the protuberant drivers supporting the growth of global eye allergy treatment market are identified as, increasing prevalence of ophthalmological disorders as rising aging population and changing lifestyle are promoting the rising prevalence of ophthalmological disorders. Favorable government funding by in developed and few developing countries in various government and private organizations are contributing to research and prevention programs for ophthalmic disorders.
Synopsis/Market Dynamics
Constant advancements in the field of treatment of eye allergies to treat patients of every age are propelling the growth of the market. For instance, Bausch & Lomb (a subsidiary of Valeant) develops the new topical corticosteroid, mapracorat (undergoing clinical phase II). Mapracorat is an ophthalmic solution for the treatment of ocular pain and inflammation, eye allergies, and dry eyes. Additionally, companies such as Merck and Co. offers montelukast, a leukotriene receptor antagonist, which is effective in alleviating allergic eye diseases. Several manufacturers are also developing innovative ophthalmic solutions and getting them approved by government regulatory bodies. Additionally, increased competition among existing and new market players to develop feasible and efficient treatments for eye allergies are also contributing to the growth of the market.
Global Eye Allergy Treatment Market Revenue, by Treatment, 2017 (USD Mn)
Sources: MRFR Analysis
Eye Allergy Treatment Market Segmentation
Global eye allergy treatment market has been segmented into type, treatment, and end user.
On the basis of type, it is segmented into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, giant papillary conjunctivitis, and others. Vernal keratoconjunctivitis includes palpebral, limbal, corneal, and others.
On the basis of treatment, the eye allergy treatment market has been segmented into medication, allergy shots (immunotherapy), and others. Medication includes artificial tears, decongestants, oral antihistamines, antihistamine/mast-cell stabilizers, corticosteroids. Decongestants are further sub-segmented into with or without antihistamines. Allergy shots (immunotherapy) is sub-segmented into Subcutaneous Immunotherapy Treatment (SCIT) and Sublingual Immunotherapy Treatment (SLIT). The medication segment is projected to value 1860.78 million in 2023. Its larger market share is due to its effectiveness for the treatment of eye allergy. Moreover, with a lot of options available in the eye allergy treatment market, patients find medications much more acceptable in most cases. The wide acceptance of artificial tear as a first-line treatment option for eye allergy is driving the market.
On the basis of end user, it is segmented into eye hospitals & clinics, medical institutes, research centers, and others.
Global Eye Allergy Treatment Market Share, by Region, 2017 (%)
Â
Sources: MRFR Analysis
Eye Allergy Treatment Market Regional Analysis
The Americas acquired the largest share of 40.4% is projected to grow at the highest CAGR during the forecast period. The growth of the Americas is due to its rising geriatric population and increasing ophthalmological disorders, causing an increased need for diagnosis and therapeutics. According to the National Eye Institute (NEI), about 3 million cases of conjunctivitis were reported in the US in 2015. This huge prevalence of eye allergies is driving the growth of the eye allergy treatment market.
Additionally, according to the US Census Bureau, in 2016, around 49.2 million residents were aged 65 and above in the US. This huge older population of the US contributed to over 15.2% of the total population which is likely to drive the market. Furthermore, the Americas is witnessing rampant advancements in technology. Thus, this increasing patient pool and increasing per capita income of citizens are going to propel the market growth of eye allergy treatments.
Americas region is followed by Europe, which accounted for the second largest eye allergy treatment market share owing to the rising patient population with eye disorders, availability of advanced treatment facilities, increasing healthcare expenditure, and the introduction of advanced therapies into the market along with the presence of good healthcare infrastructure. Additionally, rising government initiatives are driving the growth of the market. According to reports published by the United Kingdom Statistics Authority, in 2015, around 15,900 people were registered as visually impaired.
Asia-Pacific is the fastest-growing market for the global eye allergy treatment market. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the eye allergy treatment market in Asia-Pacific. Additionally, the rising elderly population is also fueling the market of eye allergy treatments in this region. According to the Asian Development Bank, Asia's elderly population is projected to reach nearly 923 million by 2050. This huge geriatric population is driving the growth of the market.
Eye Allergy Treatment Market Key Players
The prominent players in the global eye allergy treatment market are Allergan Plc, Johnson & Johnson Services Inc, Novartis AG, Bausch Health (Valeant Pharmaceuticals International Inc.), Santen Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, Nicox, Akorn Inc., Shire, Nutra Essential OTC, and others.
Some of the key strategies followed by the players operating in the global eye allergy treatment market were innovation, product development, acquisition, and expansion.
- In 2017 the Novartis AG launched olopatadine hydrochloride ophthalmic solution, a generic version of Pataday eye drop. It is used in the treatment of allergic conjunctivitis. The firm has a presence across the world that enhances its market share.
- Santen Pharmaceutical Co. Ltd, in October 2018 launched Verkazia eye drops emulsion.
- Allergan Plc, in August 2016, acquired ForSight VISION5 Inc. (US). With this acquisition, the company aims to strengthen its eye care products portfolio and widen its geographic presence.
Eye Allergy Treatment Market Segmentation
Global Eye Allergy Treatment Market, by Type
- Seasonal and Perennial Allergic Conjunctivitis
- Vernal Keratoconjunctivitis
- Atopic Keratoconjunctivitis
- Contact Allergic Conjunctivitis
- Giant Papillary Conjunctivitis
Global Eye Allergy Treatment Market, by Treatment
- Medications
- Artificial Tears
- Decongestants
- Antihistamine/Mast-Cell Stabilizers
- Oral Antihistamines
- Corticosteroids
- Allergy Shots (Immunotherapy)
- Subcutaneous Immunotherapy Treatment (SCIT)
- Sublingual Immunotherapy Treatment (SLIT)
Global Eye Allergy Treatment Market, by End User
- Hospitals and Clinics
- Specialty Centers
Global Eye Allergy Treatment Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- Russia
- France
- Italy
- UK
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
Available Additional Customizations
- Company Profiles of Other Key Players
- Pfizer Inc. (US)
- Regeneron Pharmaceuticals, Inc. (US)
- Hoffmann-La Roche Ltd (Switzerland)
- Santen Pharmaceutical Co., Ltd (Japan)
- Valeant (Canada)
- End User Analysis (Example)
Technological Trends-
Rising new market entrants offering new products for the treatment of eye allergy is driving the growth of the market. The introduction of technologically-advanced and innovative products is driving the eye allergy treatment market. For instance, market players such as Novartis launched Olopatadine Hydrochloride, an ophthalmic solution for the treatment of allergic conjunctivitis. Santen launched Verkazia eye drops emulsion, for the treatment of severe vernal keratoconjunctivitis in children. Additionally, Bausch & Lomb (a subsidiary of Valeant) develops the new topical corticosteroid, mapracorat for the treatment of eye allergy symptoms which is in clinical phase II. These technological advancements and innovations in products are contributing to the growth of eye allergy treatment market.
Intended Audience
- Eye allergy treatment medicines’ manufacturers
- Eye allergy treatment medicine and treatment providers
- Hospitals and clinics
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
